RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1
- Registration Number
- NCT02117050
- Locations
- 🇺🇸
Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 15
- Registration Number
- NCT02083679
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
🇺🇸Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 253
- Registration Number
- NCT02070978
- Locations
- 🇲🇽
Clinica de Enfermedades Cronicas y de Procedimientos Especiales, S.C., Morelia, Michoacán, Mexico
🇵🇭Mary Mediatrix Medical Center, Batangas, Philippines
🇲🇽Icle S.C., Guadalajara, Jalisco, Mexico
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 35
- Registration Number
- NCT02049151
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 97
- Registration Number
- NCT02019550
- Locations
- 🇺🇸
Research site, Mansfield, Texas, United States
🇺🇸Research Site, Knoxville, Tennessee, United States
Relative Bioavailability of Pimasertib in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 38
- Registration Number
- NCT01992874
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 12
- Registration Number
- NCT01973608
- Locations
- 🇺🇸
Please Contact U.S. Medical Information, Rockland, Massachusetts, United States
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 306
- Registration Number
- NCT01972568
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇦🇷Atencion Integral en Reumatologia (AIR), Ciudad Autonoma Buenos Aires, Argentina
🇦🇷Organizacion Medica de Investigacion (OMI), Ciudad Autonoma Buenos Aires, Argentina
First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 101
- Registration Number
- NCT01971515
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California at San Diego, Moores Cancer Center, San Diego, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 255
- Registration Number
- NCT01963611
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
🇬🇧Research site, Stoke on Trent, United Kingdom